{"entity":{"type":"insider","cik":"0001347769","url":"/insider/0001347769","json_url":"/insider/0001347769.json","name":"COLUMN GROUP L P","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":282,"n_filings":126,"first":"2014-07-31","last":"2023-11-17","span_basis":"filed_date"},"name_variants":[{"name":"COLUMN GROUP L P","source":"filing","n_filings":126,"first_seen":"2014-07-31","last_seen":"2023-11-17"}],"transactions":[{"id":8750030,"accession":"0000950170-23-064847","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-23-064847","line_url":"/filing/0000950170-23-064847#line-2","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"COLUMN GROUP II, LP; COLUMN GROUP L P; Column Group II GP, LP; Column Group Management LP; Kutzkey Tim; PONOI CAPITAL, LP; Ponoi Capital II, LP; Ponoi II Management, LLC; Ponoi Management, LLC; Svennilson Peter","owner_display_name":"COLUMN GROUP II, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5840.0,"shares_display":"5,840","price_per_share":0.6211,"price_display":"0.62","price_state":"stated","total_value":3627.224,"total_display":"3,627.22","total_whole":"3,627","shares_owned_after":949862.0,"shares_owned_after_display":"949,862","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-16","filed_date":"2023-11-17","scope":"insider"},{"id":8530688,"accession":"0000950170-23-064858","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-23-064858","line_url":"/filing/0000950170-23-064858#line-2","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"COLUMN GROUP L P; TCG Opportunity III GP, LLC","owner_display_name":"COLUMN GROUP L P","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5840.0,"shares_display":"5,840","price_per_share":0.6211,"price_display":"0.62","price_state":"stated","total_value":3627.224,"total_display":"3,627.22","total_whole":"3,627","shares_owned_after":949862.0,"shares_owned_after_display":"949,862","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-16","filed_date":"2023-11-17","scope":"insider"},{"id":8530681,"accession":"0000950170-23-064854","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-23-064854","line_url":"/filing/0000950170-23-064854#line-2","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"COLUMN GROUP GP, LP; COLUMN GROUP III, LP; COLUMN GROUP III-A, LP; COLUMN GROUP L P; Column Group IV GP, LP; Column Group IV, LP; Column Group IV-A, LP; Column Group Opportunity III GP, LP; Column Group Opportunity III, LP; TCG IV GP, LLC","owner_display_name":"COLUMN GROUP GP, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5840.0,"shares_display":"5,840","price_per_share":0.6211,"price_display":"0.62","price_state":"stated","total_value":3627.224,"total_display":"3,627.22","total_whole":"3,627","shares_owned_after":949862.0,"shares_owned_after_display":"949,862","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-16","filed_date":"2023-11-17","scope":"insider"},{"id":8750026,"accession":"0000950170-23-064847","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-23-064847","line_url":"/filing/0000950170-23-064847#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"COLUMN GROUP II, LP; COLUMN GROUP L P; Column Group II GP, LP; Column Group Management LP; Kutzkey Tim; PONOI CAPITAL, LP; Ponoi Capital II, LP; Ponoi II Management, LLC; Ponoi Management, LLC; Svennilson Peter","owner_display_name":"COLUMN GROUP II, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":16791.0,"shares_display":"16,791","price_per_share":0.7075,"price_display":"0.71","price_state":"stated","total_value":11879.6325,"total_display":"11,879.63","total_whole":"11,880","shares_owned_after":944022.0,"shares_owned_after_display":"944,022","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-15","filed_date":"2023-11-17","scope":"insider"},{"id":8530685,"accession":"0000950170-23-064858","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-23-064858","line_url":"/filing/0000950170-23-064858#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"COLUMN GROUP L P; TCG Opportunity III GP, LLC","owner_display_name":"COLUMN GROUP L P","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":16791.0,"shares_display":"16,791","price_per_share":0.7075,"price_display":"0.71","price_state":"stated","total_value":11879.6325,"total_display":"11,879.63","total_whole":"11,880","shares_owned_after":944022.0,"shares_owned_after_display":"944,022","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-15","filed_date":"2023-11-17","scope":"insider"},{"id":8530677,"accession":"0000950170-23-064854","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-23-064854","line_url":"/filing/0000950170-23-064854#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"COLUMN GROUP GP, LP; COLUMN GROUP III, LP; COLUMN GROUP III-A, LP; COLUMN GROUP L P; Column Group IV GP, LP; Column Group IV, LP; Column Group IV-A, LP; Column Group Opportunity III GP, LP; Column Group Opportunity III, LP; TCG IV GP, LLC","owner_display_name":"COLUMN GROUP GP, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":16791.0,"shares_display":"16,791","price_per_share":0.7075,"price_display":"0.71","price_state":"stated","total_value":11879.6325,"total_display":"11,879.63","total_whole":"11,880","shares_owned_after":944022.0,"shares_owned_after_display":"944,022","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-15","filed_date":"2023-11-17","scope":"insider"},{"id":8010048,"accession":"0000899243-23-003130","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-003130","line_url":"/filing/0000899243-23-003130#line-2","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"Ponoi Capital II, LP; PONOI CAPITAL, LP; Column Group II GP, LP; Column Group Management LP; COLUMN GROUP II, LP; Svennilson Peter; COLUMN GROUP L P; Ponoi Management, LLC; Kutzkey Tim; Ponoi II Management, LLC","owner_display_name":"Ponoi Capital II, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":176730.0,"shares_display":"176,730","price_per_share":4.9986,"price_display":"5.00","price_state":"stated","total_value":883402.578,"total_display":"883,402.58","total_whole":"883,403","shares_owned_after":927231.0,"shares_owned_after_display":"927,231","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-31","filed_date":"2023-02-01","scope":"insider"},{"id":7987197,"accession":"0000899243-23-003137","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-003137","line_url":"/filing/0000899243-23-003137#line-2","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"Column Group Opportunity III, LP; Column Group IV GP, LP; COLUMN GROUP L P; COLUMN GROUP III-A, LP; COLUMN GROUP III, LP; Column Group IV-A, LP; COLUMN GROUP GP, LP; TCG IV GP, LLC; Column Group IV, LP; Column Group Opportunity III GP, LP","owner_display_name":"Column Group Opportunity III, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":176730.0,"shares_display":"176,730","price_per_share":4.9986,"price_display":"5.00","price_state":"stated","total_value":883402.578,"total_display":"883,402.58","total_whole":"883,403","shares_owned_after":927231.0,"shares_owned_after_display":"927,231","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-31","filed_date":"2023-02-01","scope":"insider"},{"id":7833963,"accession":"0000899243-23-003132","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-003132","line_url":"/filing/0000899243-23-003132#line-2","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"TCG Opportunity III GP, LLC; COLUMN GROUP L P","owner_display_name":"TCG Opportunity III GP, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":176730.0,"shares_display":"176,730","price_per_share":4.9986,"price_display":"5.00","price_state":"stated","total_value":883402.578,"total_display":"883,402.58","total_whole":"883,403","shares_owned_after":927231.0,"shares_owned_after_display":"927,231","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-31","filed_date":"2023-02-01","scope":"insider"},{"id":8010044,"accession":"0000899243-23-003130","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-003130","line_url":"/filing/0000899243-23-003130#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"Ponoi Capital II, LP; PONOI CAPITAL, LP; Column Group II GP, LP; Column Group Management LP; COLUMN GROUP II, LP; Svennilson Peter; COLUMN GROUP L P; Ponoi Management, LLC; Kutzkey Tim; Ponoi II Management, LLC","owner_display_name":"Ponoi Capital II, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7542.0,"shares_display":"7,542","price_per_share":4.9996,"price_display":"5.00","price_state":"stated","total_value":37706.9832,"total_display":"37,706.98","total_whole":"37,707","shares_owned_after":750501.0,"shares_owned_after_display":"750,501","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-30","filed_date":"2023-02-01","scope":"insider"},{"id":7987193,"accession":"0000899243-23-003137","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-003137","line_url":"/filing/0000899243-23-003137#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"Column Group Opportunity III, LP; Column Group IV GP, LP; COLUMN GROUP L P; COLUMN GROUP III-A, LP; COLUMN GROUP III, LP; Column Group IV-A, LP; COLUMN GROUP GP, LP; TCG IV GP, LLC; Column Group IV, LP; Column Group Opportunity III GP, LP","owner_display_name":"Column Group Opportunity III, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7542.0,"shares_display":"7,542","price_per_share":4.9996,"price_display":"5.00","price_state":"stated","total_value":37706.9832,"total_display":"37,706.98","total_whole":"37,707","shares_owned_after":750501.0,"shares_owned_after_display":"750,501","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-30","filed_date":"2023-02-01","scope":"insider"},{"id":7833960,"accession":"0000899243-23-003132","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-003132","line_url":"/filing/0000899243-23-003132#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"TCG Opportunity III GP, LLC; COLUMN GROUP L P","owner_display_name":"TCG Opportunity III GP, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7542.0,"shares_display":"7,542","price_per_share":4.9996,"price_display":"5.00","price_state":"stated","total_value":37706.9832,"total_display":"37,706.98","total_whole":"37,707","shares_owned_after":750501.0,"shares_owned_after_display":"750,501","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-30","filed_date":"2023-02-01","scope":"insider"},{"id":8694188,"accession":"0000899243-23-002642","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-002642","line_url":"/filing/0000899243-23-002642#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"TCG Opportunity III GP, LLC; COLUMN GROUP L P","owner_display_name":"TCG Opportunity III GP, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9900.0,"shares_display":"9,900","price_per_share":4.9994,"price_display":"5.00","price_state":"stated","total_value":49494.06,"total_display":"49,494.06","total_whole":"49,494","shares_owned_after":742959.0,"shares_owned_after_display":"742,959","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-23","filed_date":"2023-01-25","scope":"insider"},{"id":8350602,"accession":"0000899243-23-002637","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-002637","line_url":"/filing/0000899243-23-002637#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"COLUMN GROUP L P; Column Group IV GP, LP; Column Group Opportunity III, LP; COLUMN GROUP III, LP; Column Group IV-A, LP; Column Group IV, LP; Column Group Opportunity III GP, LP; COLUMN GROUP GP, LP; TCG IV GP, LLC; COLUMN GROUP III-A, LP","owner_display_name":"COLUMN GROUP L P","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9900.0,"shares_display":"9,900","price_per_share":4.9994,"price_display":"5.00","price_state":"stated","total_value":49494.06,"total_display":"49,494.06","total_whole":"49,494","shares_owned_after":742959.0,"shares_owned_after_display":"742,959","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-23","filed_date":"2023-01-25","scope":"insider"},{"id":8279106,"accession":"0000899243-23-002630","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-002630","line_url":"/filing/0000899243-23-002630#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"Ponoi II Management, LLC; Svennilson Peter; Column Group Management LP; COLUMN GROUP L P; Ponoi Management, LLC; Column Group II GP, LP; PONOI CAPITAL, LP; Kutzkey Tim; Ponoi Capital II, LP; COLUMN GROUP II, LP","owner_display_name":"Ponoi II Management, LLC","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9900.0,"shares_display":"9,900","price_per_share":4.9994,"price_display":"5.00","price_state":"stated","total_value":49494.06,"total_display":"49,494.06","total_whole":"49,494","shares_owned_after":742959.0,"shares_owned_after_display":"742,959","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-23","filed_date":"2023-01-25","scope":"insider"},{"id":8740598,"accession":"0000899243-23-002381","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-002381","line_url":"/filing/0000899243-23-002381#line-2","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"TCG Opportunity III GP, LLC; COLUMN GROUP L P","owner_display_name":"TCG Opportunity III GP, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500.0,"shares_display":"500","price_per_share":4.996,"price_display":"5.00","price_state":"stated","total_value":2498.0,"total_display":"2,498.00","total_whole":"2,498","shares_owned_after":733059.0,"shares_owned_after_display":"733,059","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-20","filed_date":"2023-01-23","scope":"insider"},{"id":8644229,"accession":"0000899243-23-002375","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-002375","line_url":"/filing/0000899243-23-002375#line-2","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"Ponoi Management, LLC; PONOI CAPITAL, LP; Column Group II GP, LP; Svennilson Peter; Column Group Management LP; Ponoi II Management, LLC; Ponoi Capital II, LP; COLUMN GROUP L P; Kutzkey Tim; COLUMN GROUP II, LP","owner_display_name":"Ponoi Management, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500.0,"shares_display":"500","price_per_share":4.996,"price_display":"5.00","price_state":"stated","total_value":2498.0,"total_display":"2,498.00","total_whole":"2,498","shares_owned_after":733059.0,"shares_owned_after_display":"733,059","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-20","filed_date":"2023-01-23","scope":"insider"},{"id":8350589,"accession":"0000899243-23-002380","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-002380","line_url":"/filing/0000899243-23-002380#line-2","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"Column Group IV GP, LP; TCG IV GP, LLC; COLUMN GROUP GP, LP; Column Group IV, LP; Column Group Opportunity III, LP; COLUMN GROUP L P; COLUMN GROUP III, LP; Column Group IV-A, LP; COLUMN GROUP III-A, LP; Column Group Opportunity III GP, LP","owner_display_name":"Column Group IV GP, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500.0,"shares_display":"500","price_per_share":4.996,"price_display":"5.00","price_state":"stated","total_value":2498.0,"total_display":"2,498.00","total_whole":"2,498","shares_owned_after":733059.0,"shares_owned_after_display":"733,059","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-20","filed_date":"2023-01-23","scope":"insider"},{"id":8740595,"accession":"0000899243-23-002381","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-002381","line_url":"/filing/0000899243-23-002381#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"TCG Opportunity III GP, LLC; COLUMN GROUP L P","owner_display_name":"TCG Opportunity III GP, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":37639.0,"shares_display":"37,639","price_per_share":4.9976,"price_display":"5.00","price_state":"stated","total_value":188104.6664,"total_display":"188,104.67","total_whole":"188,105","shares_owned_after":732559.0,"shares_owned_after_display":"732,559","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-19","filed_date":"2023-01-23","scope":"insider"},{"id":8644226,"accession":"0000899243-23-002375","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-002375","line_url":"/filing/0000899243-23-002375#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"Ponoi Management, LLC; PONOI CAPITAL, LP; Column Group II GP, LP; Svennilson Peter; Column Group Management LP; Ponoi II Management, LLC; Ponoi Capital II, LP; COLUMN GROUP L P; Kutzkey Tim; COLUMN GROUP II, LP","owner_display_name":"Ponoi Management, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":37639.0,"shares_display":"37,639","price_per_share":4.9976,"price_display":"5.00","price_state":"stated","total_value":188104.6664,"total_display":"188,104.67","total_whole":"188,105","shares_owned_after":732559.0,"shares_owned_after_display":"732,559","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-19","filed_date":"2023-01-23","scope":"insider"},{"id":8350582,"accession":"0000899243-23-002380","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-002380","line_url":"/filing/0000899243-23-002380#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"Column Group IV GP, LP; TCG IV GP, LLC; COLUMN GROUP GP, LP; Column Group IV, LP; Column Group Opportunity III, LP; COLUMN GROUP L P; COLUMN GROUP III, LP; Column Group IV-A, LP; COLUMN GROUP III-A, LP; Column Group Opportunity III GP, LP","owner_display_name":"Column Group IV GP, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":37639.0,"shares_display":"37,639","price_per_share":4.9976,"price_display":"5.00","price_state":"stated","total_value":188104.6664,"total_display":"188,104.67","total_whole":"188,105","shares_owned_after":732559.0,"shares_owned_after_display":"732,559","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-19","filed_date":"2023-01-23","scope":"insider"},{"id":8619898,"accession":"0000899243-23-001854","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-001854","line_url":"/filing/0000899243-23-001854#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"Svennilson Peter; Column Group II GP, LP; Ponoi Management, LLC; Ponoi II Management, LLC; COLUMN GROUP L P; Column Group Management LP; Ponoi Capital II, LP; Kutzkey Tim; COLUMN GROUP II, LP; PONOI CAPITAL, LP","owner_display_name":"Svennilson Peter","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5378.0,"shares_display":"5,378","price_per_share":4.9466,"price_display":"4.95","price_state":"stated","total_value":26602.8148,"total_display":"26,602.81","total_whole":"26,603","shares_owned_after":694920.0,"shares_owned_after_display":"694,920","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-12","filed_date":"2023-01-17","scope":"insider"},{"id":8421226,"accession":"0000899243-23-001857","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-001857","line_url":"/filing/0000899243-23-001857#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"TCG Opportunity III GP, LLC; COLUMN GROUP L P","owner_display_name":"TCG Opportunity III GP, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5378.0,"shares_display":"5,378","price_per_share":4.9466,"price_display":"4.95","price_state":"stated","total_value":26602.8148,"total_display":"26,602.81","total_whole":"26,603","shares_owned_after":694920.0,"shares_owned_after_display":"694,920","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-12","filed_date":"2023-01-17","scope":"insider"},{"id":8062095,"accession":"0000899243-23-001855","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-001855","line_url":"/filing/0000899243-23-001855#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"COLUMN GROUP L P; Column Group Opportunity III, LP; COLUMN GROUP III, LP; Column Group IV-A, LP; Column Group Opportunity III GP, LP; Column Group IV GP, LP; COLUMN GROUP GP, LP; TCG IV GP, LLC; Column Group IV, LP; COLUMN GROUP III-A, LP","owner_display_name":"COLUMN GROUP L P","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5378.0,"shares_display":"5,378","price_per_share":4.9466,"price_display":"4.95","price_state":"stated","total_value":26602.8148,"total_display":"26,602.81","total_whole":"26,603","shares_owned_after":694920.0,"shares_owned_after_display":"694,920","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-12","filed_date":"2023-01-17","scope":"insider"},{"id":8720417,"accession":"0000899243-23-001695","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-001695","line_url":"/filing/0000899243-23-001695#line-2","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"Column Group IV GP, LP; TCG IV GP, LLC; COLUMN GROUP GP, LP; Column Group Opportunity III, LP; COLUMN GROUP L P; COLUMN GROUP III, LP; Column Group IV-A, LP; COLUMN GROUP III-A, LP; Column Group Opportunity III GP, LP; Column Group IV, LP","owner_display_name":"Column Group IV GP, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":209000.0,"shares_display":"209,000","price_per_share":4.76,"price_display":"4.76","price_state":"stated","total_value":994840.0,"total_display":"994,840.00","total_whole":"994,840","shares_owned_after":689542.0,"shares_owned_after_display":"689,542","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-11","filed_date":"2023-01-12","scope":"insider"},{"id":8527664,"accession":"0000899243-23-001694","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-001694","line_url":"/filing/0000899243-23-001694#line-2","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"Ponoi Management, LLC; PONOI CAPITAL, LP; Column Group II GP, LP; Svennilson Peter; Column Group Management LP; Ponoi II Management, LLC; Ponoi Capital II, LP; COLUMN GROUP L P; Kutzkey Tim; COLUMN GROUP II, LP","owner_display_name":"Ponoi Management, LLC","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":209000.0,"shares_display":"209,000","price_per_share":4.76,"price_display":"4.76","price_state":"stated","total_value":994840.0,"total_display":"994,840.00","total_whole":"994,840","shares_owned_after":689542.0,"shares_owned_after_display":"689,542","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-11","filed_date":"2023-01-12","scope":"insider"},{"id":8421214,"accession":"0000899243-23-001697","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-001697","line_url":"/filing/0000899243-23-001697#line-2","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"TCG Opportunity III GP, LLC; COLUMN GROUP L P","owner_display_name":"TCG Opportunity III GP, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":209000.0,"shares_display":"209,000","price_per_share":4.76,"price_display":"4.76","price_state":"stated","total_value":994840.0,"total_display":"994,840.00","total_whole":"994,840","shares_owned_after":689542.0,"shares_owned_after_display":"689,542","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-11","filed_date":"2023-01-12","scope":"insider"},{"id":8720414,"accession":"0000899243-23-001695","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-001695","line_url":"/filing/0000899243-23-001695#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"Column Group IV GP, LP; TCG IV GP, LLC; COLUMN GROUP GP, LP; Column Group Opportunity III, LP; COLUMN GROUP L P; COLUMN GROUP III, LP; Column Group IV-A, LP; COLUMN GROUP III-A, LP; Column Group Opportunity III GP, LP; Column Group IV, LP","owner_display_name":"Column Group IV GP, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100070.0,"shares_display":"100,070","price_per_share":4.8418,"price_display":"4.84","price_state":"stated","total_value":484518.926,"total_display":"484,518.93","total_whole":"484,519","shares_owned_after":480542.0,"shares_owned_after_display":"480,542","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-10","filed_date":"2023-01-12","scope":"insider"},{"id":8527658,"accession":"0000899243-23-001694","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-001694","line_url":"/filing/0000899243-23-001694#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"Ponoi Management, LLC; PONOI CAPITAL, LP; Column Group II GP, LP; Svennilson Peter; Column Group Management LP; Ponoi II Management, LLC; Ponoi Capital II, LP; COLUMN GROUP L P; Kutzkey Tim; COLUMN GROUP II, LP","owner_display_name":"Ponoi Management, LLC","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100070.0,"shares_display":"100,070","price_per_share":4.8418,"price_display":"4.84","price_state":"stated","total_value":484518.926,"total_display":"484,518.93","total_whole":"484,519","shares_owned_after":480542.0,"shares_owned_after_display":"480,542","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-10","filed_date":"2023-01-12","scope":"insider"},{"id":8421209,"accession":"0000899243-23-001697","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-001697","line_url":"/filing/0000899243-23-001697#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"TCG Opportunity III GP, LLC; COLUMN GROUP L P","owner_display_name":"TCG Opportunity III GP, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100070.0,"shares_display":"100,070","price_per_share":4.8418,"price_display":"4.84","price_state":"stated","total_value":484518.926,"total_display":"484,518.93","total_whole":"484,519","shares_owned_after":480542.0,"shares_owned_after_display":"480,542","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-10","filed_date":"2023-01-12","scope":"insider"},{"id":6805069,"accession":"0000899243-22-038465","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-038465","line_url":"/filing/0000899243-22-038465#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"PONOI CAPITAL, LP; COLUMN GROUP II, LP; Ponoi II Management, LLC; Kutzkey Tim; Ponoi Management, LLC; Svennilson Peter; Column Group II GP, LP; Column Group Management LP; Ponoi Capital II, LP; COLUMN GROUP L P","owner_display_name":"PONOI CAPITAL, LP","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300.0,"shares_display":"300","price_per_share":4.9767,"price_display":"4.98","price_state":"stated","total_value":1493.01,"total_display":"1,493.01","total_whole":"1,493","shares_owned_after":380472.0,"shares_owned_after_display":"380,472","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-12-12","filed_date":"2022-12-14","scope":"insider"},{"id":6444408,"accession":"0000899243-22-038466","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-038466","line_url":"/filing/0000899243-22-038466#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"Column Group Opportunity III GP, LP; Column Group Opportunity III, LP; Column Group IV GP, LP; COLUMN GROUP L P; COLUMN GROUP III-A, LP; COLUMN GROUP GP, LP; Column Group IV, LP; COLUMN GROUP III, LP; Column Group IV-A, LP; TCG IV GP, LLC","owner_display_name":"Column Group Opportunity III GP, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300.0,"shares_display":"300","price_per_share":4.9767,"price_display":"4.98","price_state":"stated","total_value":1493.01,"total_display":"1,493.01","total_whole":"1,493","shares_owned_after":380472.0,"shares_owned_after_display":"380,472","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-12-12","filed_date":"2022-12-14","scope":"insider"},{"id":6386757,"accession":"0000899243-22-038468","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-038468","line_url":"/filing/0000899243-22-038468#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"TCG Opportunity III GP, LLC; COLUMN GROUP L P","owner_display_name":"TCG Opportunity III GP, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300.0,"shares_display":"300","price_per_share":4.9767,"price_display":"4.98","price_state":"stated","total_value":1493.01,"total_display":"1,493.01","total_whole":"1,493","shares_owned_after":380472.0,"shares_owned_after_display":"380,472","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-12-12","filed_date":"2022-12-14","scope":"insider"},{"id":6444318,"accession":"0000899243-22-036916","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-036916","line_url":"/filing/0000899243-22-036916#line-2","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"COLUMN GROUP III-A, LP; TCG IV GP, LLC; COLUMN GROUP GP, LP; COLUMN GROUP III, LP; Column Group IV-A, LP; COLUMN GROUP L P; Column Group IV GP, LP; Column Group Opportunity III, LP; Column Group IV, LP; Column Group Opportunity III GP, LP","owner_display_name":"COLUMN GROUP III-A, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4330.0,"shares_display":"4,330","price_per_share":4.9991,"price_display":"5.00","price_state":"stated","total_value":21646.103,"total_display":"21,646.10","total_whole":"21,646","shares_owned_after":380172.0,"shares_owned_after_display":"380,172","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-22","filed_date":"2022-11-23","scope":"insider"},{"id":6167694,"accession":"0000899243-22-036919","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-036919","line_url":"/filing/0000899243-22-036919#line-2","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"TCG Opportunity III GP, LLC; COLUMN GROUP L P","owner_display_name":"TCG Opportunity III GP, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4330.0,"shares_display":"4,330","price_per_share":4.9991,"price_display":"5.00","price_state":"stated","total_value":21646.103,"total_display":"21,646.10","total_whole":"21,646","shares_owned_after":380172.0,"shares_owned_after_display":"380,172","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-22","filed_date":"2022-11-23","scope":"insider"},{"id":6118189,"accession":"0000899243-22-036912","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-036912","line_url":"/filing/0000899243-22-036912#line-2","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"COLUMN GROUP II, LP; Ponoi II Management, LLC; Ponoi Capital II, LP; COLUMN GROUP L P; PONOI CAPITAL, LP; Svennilson Peter; Ponoi Management, LLC; Kutzkey Tim; Column Group Management LP; Column Group II GP, LP","owner_display_name":"COLUMN GROUP II, LP","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4330.0,"shares_display":"4,330","price_per_share":4.9991,"price_display":"5.00","price_state":"stated","total_value":21646.103,"total_display":"21,646.10","total_whole":"21,646","shares_owned_after":380172.0,"shares_owned_after_display":"380,172","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-22","filed_date":"2022-11-23","scope":"insider"},{"id":6444315,"accession":"0000899243-22-036916","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-036916","line_url":"/filing/0000899243-22-036916#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"COLUMN GROUP III-A, LP; TCG IV GP, LLC; COLUMN GROUP GP, LP; COLUMN GROUP III, LP; Column Group IV-A, LP; COLUMN GROUP L P; Column Group IV GP, LP; Column Group Opportunity III, LP; Column Group IV, LP; Column Group Opportunity III GP, LP","owner_display_name":"COLUMN GROUP III-A, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":35997.0,"shares_display":"35,997","price_per_share":4.9988,"price_display":"5.00","price_state":"stated","total_value":179941.8036,"total_display":"179,941.80","total_whole":"179,942","shares_owned_after":375842.0,"shares_owned_after_display":"375,842","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-21","filed_date":"2022-11-23","scope":"insider"},{"id":6167690,"accession":"0000899243-22-036919","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-036919","line_url":"/filing/0000899243-22-036919#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"TCG Opportunity III GP, LLC; COLUMN GROUP L P","owner_display_name":"TCG Opportunity III GP, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":35997.0,"shares_display":"35,997","price_per_share":4.9988,"price_display":"5.00","price_state":"stated","total_value":179941.8036,"total_display":"179,941.80","total_whole":"179,942","shares_owned_after":375842.0,"shares_owned_after_display":"375,842","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-21","filed_date":"2022-11-23","scope":"insider"},{"id":6118184,"accession":"0000899243-22-036912","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-036912","line_url":"/filing/0000899243-22-036912#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"COLUMN GROUP II, LP; Ponoi II Management, LLC; Ponoi Capital II, LP; COLUMN GROUP L P; PONOI CAPITAL, LP; Svennilson Peter; Ponoi Management, LLC; Kutzkey Tim; Column Group Management LP; Column Group II GP, LP","owner_display_name":"COLUMN GROUP II, LP","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":35997.0,"shares_display":"35,997","price_per_share":4.9988,"price_display":"5.00","price_state":"stated","total_value":179941.8036,"total_display":"179,941.80","total_whole":"179,942","shares_owned_after":375842.0,"shares_owned_after_display":"375,842","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-21","filed_date":"2022-11-23","scope":"insider"},{"id":6841747,"accession":"0000899243-22-035274","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-035274","line_url":"/filing/0000899243-22-035274#line-2","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"Kutzkey Tim; Ponoi Management, LLC; COLUMN GROUP II, LP; Svennilson Peter; PONOI CAPITAL, LP; COLUMN GROUP L P; Ponoi Capital II, LP; Ponoi II Management, LLC; Column Group Management LP; Column Group II GP, LP","owner_display_name":"Kutzkey Tim","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":35058.0,"shares_display":"35,058","price_per_share":4.7156,"price_display":"4.72","price_state":"stated","total_value":165319.5048,"total_display":"165,319.50","total_whole":"165,320","shares_owned_after":339845.0,"shares_owned_after_display":"339,845","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-04","filed_date":"2022-11-07","scope":"insider"},{"id":6342383,"accession":"0000899243-22-035277","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-035277","line_url":"/filing/0000899243-22-035277#line-2","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"Column Group Opportunity III GP, LP; Column Group IV, LP; COLUMN GROUP III-A, LP; Column Group IV GP, LP; TCG IV GP, LLC; COLUMN GROUP GP, LP; Column Group Opportunity III, LP; COLUMN GROUP L P; COLUMN GROUP III, LP; Column Group IV-A, LP","owner_display_name":"Column Group Opportunity III GP, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":35058.0,"shares_display":"35,058","price_per_share":4.7156,"price_display":"4.72","price_state":"stated","total_value":165319.5048,"total_display":"165,319.50","total_whole":"165,320","shares_owned_after":339845.0,"shares_owned_after_display":"339,845","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-04","filed_date":"2022-11-07","scope":"insider"},{"id":6319164,"accession":"0000899243-22-035279","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-035279","line_url":"/filing/0000899243-22-035279#line-2","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"TCG Opportunity III GP, LLC; COLUMN GROUP L P","owner_display_name":"TCG Opportunity III GP, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":35058.0,"shares_display":"35,058","price_per_share":4.7156,"price_display":"4.72","price_state":"stated","total_value":165319.5048,"total_display":"165,319.50","total_whole":"165,320","shares_owned_after":339845.0,"shares_owned_after_display":"339,845","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-04","filed_date":"2022-11-07","scope":"insider"},{"id":6841742,"accession":"0000899243-22-035274","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-035274","line_url":"/filing/0000899243-22-035274#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"Kutzkey Tim; Ponoi Management, LLC; COLUMN GROUP II, LP; Svennilson Peter; PONOI CAPITAL, LP; COLUMN GROUP L P; Ponoi Capital II, LP; Ponoi II Management, LLC; Column Group Management LP; Column Group II GP, LP","owner_display_name":"Kutzkey Tim","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":104090.0,"shares_display":"104,090","price_per_share":4.9871,"price_display":"4.99","price_state":"stated","total_value":519107.239,"total_display":"519,107.24","total_whole":"519,107","shares_owned_after":304787.0,"shares_owned_after_display":"304,787","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-03","filed_date":"2022-11-07","scope":"insider"},{"id":6342379,"accession":"0000899243-22-035277","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-035277","line_url":"/filing/0000899243-22-035277#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"Column Group Opportunity III GP, LP; Column Group IV, LP; COLUMN GROUP III-A, LP; Column Group IV GP, LP; TCG IV GP, LLC; COLUMN GROUP GP, LP; Column Group Opportunity III, LP; COLUMN GROUP L P; COLUMN GROUP III, LP; Column Group IV-A, LP","owner_display_name":"Column Group Opportunity III GP, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":104090.0,"shares_display":"104,090","price_per_share":4.9871,"price_display":"4.99","price_state":"stated","total_value":519107.239,"total_display":"519,107.24","total_whole":"519,107","shares_owned_after":304787.0,"shares_owned_after_display":"304,787","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-03","filed_date":"2022-11-07","scope":"insider"},{"id":6319162,"accession":"0000899243-22-035279","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-035279","line_url":"/filing/0000899243-22-035279#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"TCG Opportunity III GP, LLC; COLUMN GROUP L P","owner_display_name":"TCG Opportunity III GP, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":104090.0,"shares_display":"104,090","price_per_share":4.9871,"price_display":"4.99","price_state":"stated","total_value":519107.239,"total_display":"519,107.24","total_whole":"519,107","shares_owned_after":304787.0,"shares_owned_after_display":"304,787","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-03","filed_date":"2022-11-07","scope":"insider"},{"id":6945351,"accession":"0000899243-22-034562","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-034562","line_url":"/filing/0000899243-22-034562#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"TCG IV GP, LLC; COLUMN GROUP L P; Column Group IV GP, LP; Column Group Opportunity III, LP; Column Group IV, LP; COLUMN GROUP GP, LP; COLUMN GROUP III-A, LP; COLUMN GROUP III, LP; Column Group IV-A, LP; Column Group Opportunity III GP, LP","owner_display_name":"TCG IV GP, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":76877.0,"shares_display":"76,877","price_per_share":4.8602,"price_display":"4.86","price_state":"stated","total_value":373637.5954,"total_display":"373,637.60","total_whole":"373,638","shares_owned_after":200697.0,"shares_owned_after_display":"200,697","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-10-27","filed_date":"2022-10-31","scope":"insider"},{"id":6201130,"accession":"0000899243-22-034563","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-034563","line_url":"/filing/0000899243-22-034563#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"COLUMN GROUP L P; TCG Opportunity III GP, LLC","owner_display_name":"COLUMN GROUP L P","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":76877.0,"shares_display":"76,877","price_per_share":4.8602,"price_display":"4.86","price_state":"stated","total_value":373637.5954,"total_display":"373,637.60","total_whole":"373,638","shares_owned_after":200697.0,"shares_owned_after_display":"200,697","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-10-27","filed_date":"2022-10-31","scope":"insider"},{"id":6089886,"accession":"0000899243-22-034559","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-034559","line_url":"/filing/0000899243-22-034559#line-1","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"Ponoi II Management, LLC; Kutzkey Tim; Column Group II GP, LP; Column Group Management LP; COLUMN GROUP L P; Ponoi Capital II, LP; COLUMN GROUP II, LP; PONOI CAPITAL, LP; Ponoi Management, LLC; Svennilson Peter","owner_display_name":"Ponoi II Management, LLC","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":76877.0,"shares_display":"76,877","price_per_share":4.8602,"price_display":"4.86","price_state":"stated","total_value":373637.5954,"total_display":"373,637.60","total_whole":"373,638","shares_owned_after":200697.0,"shares_owned_after_display":"200,697","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-10-27","filed_date":"2022-10-31","scope":"insider"},{"id":6878343,"accession":"0000899243-22-034352","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-034352","line_url":"/filing/0000899243-22-034352#line-2","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"Kutzkey Tim; Ponoi Management, LLC; Ponoi Capital II, LP; COLUMN GROUP L P; COLUMN GROUP II, LP; PONOI CAPITAL, LP; Ponoi II Management, LLC; Column Group II GP, LP; Column Group Management LP; Svennilson Peter","owner_display_name":"Kutzkey Tim","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":72774.0,"shares_display":"72,774","price_per_share":4.8512,"price_display":"4.85","price_state":"stated","total_value":353041.2288,"total_display":"353,041.23","total_whole":"353,041","shares_owned_after":123820.0,"shares_owned_after_display":"123,820","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-10-26","filed_date":"2022-10-27","scope":"insider"},{"id":6741950,"accession":"0000899243-22-034359","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-034359","line_url":"/filing/0000899243-22-034359#line-2","is_derivative":false,"issuer_cik":"0001347769","issuer_name":"NGM BIOPHARMACEUTICALS INC","issuer_ticker":"NGM","issuer_name_source":null,"issuer_url":"/issuer/0001347769","owner_cik":null,"owner_name":"COLUMN GROUP III-A, LP; COLUMN GROUP III, LP; Column Group IV-A, LP; Column Group Opportunity III GP, LP; TCG IV GP, LLC; COLUMN GROUP GP, LP; Column Group IV, LP; Column Group IV GP, LP; COLUMN GROUP L P; Column Group Opportunity III, LP","owner_display_name":"COLUMN GROUP III-A, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":72774.0,"shares_display":"72,774","price_per_share":4.8512,"price_display":"4.85","price_state":"stated","total_value":353041.2288,"total_display":"353,041.23","total_whole":"353,041","shares_owned_after":123820.0,"shares_owned_after_display":"123,820","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-10-26","filed_date":"2022-10-27","scope":"insider"}],"collapsed":true,"next_cursor":"2022-10-26|6741950","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001426332","name":"NGM BIOPHARMACEUTICALS INC","url":"/issuer/0001426332","role":"Director, Ten percent owner","n_filings":118,"first_seen":"2019-04-10","last_seen":"2023-11-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001434418","name":"CONSTELLATION PHARMACEUTICALS INC","url":"/issuer/0001434418","role":"Ten percent owner","n_filings":5,"first_seen":"2019-10-07","last_seen":"2021-02-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001437786","name":"Immune Design Corp.","url":"/issuer/0001437786","role":"Ten percent owner","n_filings":3,"first_seen":"2014-07-31","last_seen":"2017-10-30"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001347769","retrieved_at":"2026-08-24T11:23:16+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}